Patents by Inventor Roger Gomis

Roger Gomis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12312642
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER-breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER-breast cancer metastasis.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: May 27, 2025
    Assignees: FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS
    Inventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic
  • Patent number: 12233077
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Grant
    Filed: April 11, 2023
    Date of Patent: February 25, 2025
    Assignee: INBIOMOTION S.L.
    Inventors: Walter Martin Gregory, Juan Carlos Tercero, Robert E. Coleman, Roger Gomis
  • Patent number: 12196758
    Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: January 14, 2025
    Assignee: FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) and INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS
    Inventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
  • Patent number: 11892453
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: February 6, 2024
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Patent number: 11840740
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: December 12, 2023
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Patent number: 11654153
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: May 23, 2023
    Assignee: INBIOMOTION S.L.
    Inventors: Walter Martin Gregory, Juan Carlos Tercero, Robert E. Coleman, Roger Gomis
  • Patent number: 11596642
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: March 7, 2023
    Assignee: INBIOMOTION S.L.
    Inventors: Walter Martin Gregory, Juan Carlos Tercero, Roger Gomis, Robert E. Coleman
  • Patent number: 11591599
    Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: February 28, 2023
    Assignees: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis Avançais
    Inventors: Roger Gomis, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
  • Patent number: 11352673
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: June 7, 2022
    Inventors: Roger Gomis, Evarist Planet
  • Patent number: 11072831
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: July 27, 2021
    Assignees: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
    Inventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic
  • Patent number: 11041861
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: June 22, 2021
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Patent number: 11041213
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: June 22, 2021
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Patent number: 10866241
    Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: December 15, 2020
    Assignees: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
    Inventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
  • Patent number: 10793642
    Abstract: The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: October 6, 2020
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Juan Carlos Tercero
  • Publication number: 20190242898
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Application
    Filed: September 18, 2018
    Publication date: August 8, 2019
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Publication number: 20190119757
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
    Type: Application
    Filed: May 21, 2018
    Publication date: April 25, 2019
    Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis Avançats
    Inventors: Roger Gomis, Evarist Planet
  • Patent number: 10119171
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: November 6, 2018
    Assignee: InBioMotion S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Patent number: 10114022
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: October 30, 2018
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Patent number: 10047398
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: August 14, 2018
    Assignees: Fundacio Institut de Recerca Biomedica (IRB Barcelona), Institucio Catalana de Recerca I Estudis Avancats
    Inventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic
  • Patent number: 10006091
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: June 26, 2018
    Assignees: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca I Estudis Avançats
    Inventors: Roger Gomis, Evarist Planet